Hans Schikan is former CEO of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) since June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 million. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Next to his role in Asceneuron, he is currently Chairman of the Board of Complix (Belgium) and InteRNA Technologies (Netherlands), Board Member of Hansa Medical (publ, Sweden), Non-executive Director of Sobi (Swedish Orphan Biovitrum, publ, Sweden), Board Member of Wilson Therapeutics (publ, Sweden) and Member of the Top Team of the Dutch Top Sector Life Sciences & Health (Netherlands). He is Adviser of Khondrion (Netherlands) and Confo Therapeutics (Belgium). He is past Chairman of Nefarma, the Dutch Association of Research Based Pharmaceutical Industry and he was previously also Member of the Biotechnology Industry Organization’s Emerging Companies Section Governing Board (USA). He has a PharmD from Utrecht University.

  Genzyme’s product portfolio for rare genetic diseases